Phosplatin honored at the European Society of Medical Oncology (ESMO) 2018 Annual Meeting

Press Release
Written by Guest User

The first-in-human Phase I study was honored as the best poster presentation among all developmental therapeutics at the European Society of Medical Oncology (ESMO) 2018 Annual Meeting in Munich, Germany.

Guest User
Previous

Phosplatin Therapeutics receives US FDA Orphan Drug designation for the use of PT-112 in patients with Thymoma and Thymic Carcinoma
Next

Phosplatin Therapeutics Announces First Cohort Enrolled in Phase I / II Trial of PT-112 in Relapsed / Refractory Multiple Myeloma, and Receipt of FDA Orphan Drug Designation